Articles from Ataraxis AI

Ataraxis AI, an AI precision medicine company and frontier artificial intelligence (AI) research lab developing AI-powered tools for oncology, announced today that it will present eight research abstracts with Ataraxis™ Breast data at the 2025 San Antonio Breast Cancer Symposium (SABCS). Research to be presented by Ataraxis and its collaborators include extensive real-world validation of Ataraxis Breast RISK and head-to-head comparisons to the previous generation of tests, highlighting the expanding clinical utility of Ataraxis tools. Ataraxis will also present first-ever data on Ataraxis Breast NEO, a test predicting response to neoadjuvant therapy, as well as results of research from the Ataraxis frontier AI research lab focused on the development of AI foundation models and calibration of prognostic models.

Ataraxis AI, a frontier laboratory developing artificial intelligence (AI)–powered prognostic tools for oncology, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced a strategic collaboration to integrate artificial intelligence into multiple major international trials. These studies, involving data from more than 1,000 patients across randomized clinical trials, aim to identify biomarkers that can optimize treatment strategies for breast cancer, including therapies with CDK4/6 inhibitors and antibody-drug conjugates (ADCs).

Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE: OSCR), Ryan Fukushima, COO of Tempus, and others. Leading researchers from OpenAI and DeepMind also participated.

Ataraxis AI, the leading AI precision medicine company, today emerged from stealth with $4 million in seed financing co-led by Giant Ventures and Obvious Ventures. The funding, raised in 2023 but announced for the first time today, has enabled Ataraxis to develop groundbreaking AI-powered diagnostic tests that significantly enhance the prediction of patient outcomes and enable more precise, personalized treatments. The company also unveiled its first offering, Ataraxis Breast – the world’s first AI-native prognostic/predictive test for breast cancer and the most advanced clinically validated test available.